Articles from M2 Pharma (September 10, 2018)

Title	Author	Type	Words
AbbVie's board approves USD0.96 per share dividend for quarter.			115
AltiBio Announces Closes Series A Preferred Stock Financing Following Positive Proof of Concept Studies.			146
BeiGene's lifirafenib combination evaluated in solid tumour trial.			154
BloodCenter of Wisconsin wins USD5m NIH glycosciences grant.			261
BTG plc closes acquisition of Novate Medical Ltd.			219
Cyclenium Pharma, Haplogen Bioscience Awarded Eureka Label and Funding to Develop Novel Therapies in Severe Viral Diseases.			437
Cytogel Pharma LLC welcomes Alan W. Dunton, MD to board of managers.			124
Cytogel Pharma names new director.			189
EnteroBiotix Granted MHRA License, Names CEO.			220
European Commission Approves Merck's Keytruda in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALKGenomic Tumor Aberrations.			170
Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers.			581
GlaxoSmithKline plans to lay off 650 employees at US operations.			144
Immunomic Therapeutics Appoints Ambinder to its Scientific Advisory Board.			472
Innovent announces CFDA IND approval for Anti-CD47 Antibody IBI188.			231
Medivir names Dr Linda Basse as CMO.			121
Milburn Named Chief Scientific Officer at GeneCentric Therapeutics.			345
MIVI Neuroscience welcomes Dr Fred Moll to board.			135
National Comprehensive Cancer Network Adds New Recommendations for Cabometyx.			992
Novus Therapeutics to Postpone Stock Offering.			432
Opiant partners with Consort Medical to develop nasal delivery device for treating opioid overdose.			224
Orion Corporation appoints Johanna Ivaska as head and VP of Oncology Research.			188
OxThera names new chief financial officer.			144
Perrigo reports upcoming launch of US FDA approved store brand Imodium Multi-Symptom Relief equivalent.			175
Rafael Holdings reports additional investment in Rafael Pharma.			218
Summit Therapeutics claims ESKAPE pathogen targeting discovery.			173
Triumvira Inks License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates.			401
Xbrane Biopharma updates product portfolio.			170
XORTX seeks orphan designation for potential new polycystic kidney disease treatment.			218
Xspray Pharma updates the encouraging clinical data of product candidate, HyNap-Dasa.			226